CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Shortening overall treatment to 12 weeks of Simeprevir (SMV) plus PEG-IFN/RBV in treatment-naïve chronic Hepatitis C (CHC) Genotype 1 patients: assessment of baseline and week 2 on-treatment predictors of SVR
DOI 10.1055/s-0035-1551744
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Gschwantler, T Asselah, C Moreno, C Sarrazin, GR Foster, A Craxi, P Buggisch, R Ryan, O Lenz, G Van Dooren, I Lonjon-Domanec, M Schlag, M Buti
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Purpose: To assess whether Week-2 response with SMV+Peg-IFN/RBV can allow shortening treatment to 12 weeks, irrespective of baseline and on-treatment factors. Design: Phase-3, open-label study in treatment-naïve CHC genotype 1-patients with no-to-moderate fibrosis (METAVIR F0-F2). In patients with HCV-RNA < 25 IU/mL (detectable/undetectable [Roche COBAS® Taqman® LLOQ: 25 IU/mL, LLOD: 15 IU/mL]) at Week 2 and undetec…
Zitieren
Zitierempfehlung
M Gschwantler, T Asselah, C Moreno, C Sarrazin, GR Foster, A Craxi, P Buggisch, R Ryan, O Lenz, G Van Dooren, I Lonjon-Domanec, M Schlag, M Buti (2015) Shortening overall treatment to 12 weeks of Simeprevir (SMV) plus PEG-IFN/RBV in treatment-naïve chronic Hepatitis C (CHC) Genotype 1 patients: assessment of baseline and week 2 on-treatment predictors of SVR. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0035-1551744
Mit CareLit weiterarbeiten